The Minnesota State Senate has passed a resolution designating May 5 to 11, 2024, as Tardive Dyskinesia Awareness Week. This initiative aims to raise awareness about tardive dyskinesia (TD), a movement disorder that can occur in individuals treated with dopamine receptor blocking agents (DRBAs), such as antipsychotics, for serious mental health and gastrointestinal conditions. It is estimated that around 600,000 people in the U.S. are affected by TD, with a significant portion remaining undiagnosed. The resolution emphasizes the importance of recognizing the symptoms of TD, as even mild cases can have serious physical, social, and emotional repercussions.

The resolution also highlights the necessity for regular monitoring and screening for TD among patients taking DRBAs, as recommended by the American Psychiatric Association. Furthermore, it notes that clinical research has led to the FDA's approval of two treatments for adults with TD. By designating this week, the Minnesota State Senate encourages residents to educate themselves about TD and its impacts, thereby fostering greater awareness within both the public and medical communities.